GLOBAL ANTIHISTAMINE DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Regional Analysis

To learn more about this report, Request sample copy

North America is anticipated to have the highest share i.e., 46.5% of the market in 2024 owing to strong presence of leading pharmaceutical companies and established healthcare infrastructure in countries like the U.S. and Canada. The presence of well-developed economies, advanced healthcare systems and rising affordability has made North America an attractive market for international players to invest in research and development of novel antihistamine drugs. The U.S. in particular accounts for over 40% of the global antihistamine drugs sales, driven by factors such as high prescription rates and availability of various branded and generic formulations across retail pharmacies and hospitals.

Asia Pacific has emerged as the fastest-growing regional market for antihistamine drugs in recent years. The rise of Asia Pacific is chiefly attributed to increasing healthcare expenditure, rapid economic growth, growing medical needs of expanding middleclass in countries like India and China. Additionally, relatively lower manufacturing and research costs compared to developed nations have attracted Pharma giants to establish manufacturing facilities for antihistamine drugs in the region. The international pharmaceutical companies have also entered partnerships and licensing agreements with local generic drug makers to penetrate emerging Asia Pacific markets. Countries like India and China dominate Asia Pacific’s antihistamine drugs market. Rapid aging population and growth of medical tourism industry has boosted consumption of antihistamine drugs in China as allergies and other related conditions are on the rise. Overall, factors like growing patient pool, improving access and affordability are driving the antihistamine drugs market across both India and China at an impressive pace.